Abivax disclosed additional safety data for obefazimod, its experimental ulcerative colitis maintenance therapy, and the update appears to have eased recent investor concerns. Shares rose sharply after the company presented follow-on data following market volatility tied to earlier safety questions. Earlier this month, Abivax reported strong efficacy in a closely watched maintenance trial, including a higher proportion of patients on obefazimod achieving periods without symptoms compared with placebo. However, a number of reported cancer cases among obefazimod-treated participants had triggered a stock drop. The new disclosures shift attention back to risk-benefit assessment for obefazimod’s development and potential regulatory pathway.